The human amylin analog, pramlintide, reduces body weight in insulin-treated patients with Type 2 diabetes.

被引：0
|
作者：
Weyer, C [1 ]
Maggs, D [1 ]
Ruggles, J [1 ]
Fineman, M [1 ]
Burrell, T [1 ]
Kolterman, O [1 ]
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
DIABETOLOGIA | 2003年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
852
引用
收藏
页码：A295 / A295
页数：1
相关论文
共 50 条
  • [1] Pramlintide, an analog of human amylin, reduced fructosamine in patients with type I diabetes.
    Thompson, RG
    Pearson, L
    Gottlieb, A
    Kolterman, O
    DIABETES, 1996, 45 : 818 - 818
  • [2] The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus
    Fineman, M
    Weyer, C
    Maggs, DG
    Strobel, S
    Kolterman, OG
    HORMONE AND METABOLIC RESEARCH, 2002, 34 (09) : 504 - 508
  • [3] Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
    Hollander, P
    Maggs, DG
    Ruggles, JA
    Fineman, M
    Shen, L
    Kolterman, OG
    Weyer, C
    OBESITY RESEARCH, 2004, 12 (04): : 661 - 668
  • [4] Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin
    Thompson, RG
    Pearson, L
    Schoenfeld, SL
    Kolterman, OG
    DIABETES CARE, 1998, 21 (06) : 987 - 993
  • [5] Amylin replacement with pramlintide as an adjunct to insulin therapy facilitates a combined improvement in glycemic and weight control in type 2 diabetes.
    Maggs, DG
    Weyer, C
    Burrell, T
    Gottlieb, AD
    Shen, LZ
    Kolterman, OG
    DIABETOLOGIA, 2001, 44 : A237 - A237
  • [6] Amylin replacement with pramlintide as an adjunct to insulin therapy facilitates a combined improvement in glycemic and weight control in type 2 diabetes.
    Maggs, DG
    Weyer, C
    Burrell, T
    Gottlieb, AD
    Shen, LZ
    Kolterman, OG
    DIABETOLOGIA, 2001, 44 : A237 - A237
  • [7] Pramlintide, an analog of human amylin improves glycemic control in patients with type II diabetes requiring insulin.
    Thompson, R
    Pearson, L
    Schoenfeld, S
    Kolterman, O
    DIABETES, 1997, 46 : 116 - 116
  • [8] The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type I diabetes
    Fineman, MS
    Koda, JE
    Shen, LZ
    Strobel, SA
    Maggs, DG
    Weyer, C
    Kolterman, OG
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (05): : 636 - 641
  • [9] Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes
    Umpierrez, Guillermo E.
    O'Neal, David
    DiGenio, Andres
    Goldenberg, Ronald
    Hernandez-Triana, Eric
    Lin, Jay
    Park, Cheol-Young
    Renard, Eric
    Kovatchev, Boris
    DIABETES OBESITY & METABOLISM, 2017, 19 (09): : 1317 - 1321
  • [10] Effect of pramlintide on A1C and body weight in insulin-treated African Americans and hispanics with type 2 diabetes:: A pooled post hoc analysis
    Maggs, D
    Shen, L
    Strobel, S
    Brown, D
    Kolterman, O
    Weyer, C
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (12): : 1638 - 1642
12345